Compare Quest Diagnostics Inc (DGX) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Prologis Inc — how do they compare? Quest Diagnostics Inc trades at $237.07 (market cap $26.21B), while Prologis Inc trades at $138.73 (market cap $132.57B). The key difference: Prologis Inc is far larger — about 5.1× Quest Diagnostics Inc's market cap, and Prologis Inc pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| DGX | PLD | |
|---|---|---|
Market Cap | $26.21B | $132.57B |
Sector | Health | Real Estate |
52-Week High | $238.50 | $149.96 |
52-Week Low | $173.49 | $104.81 |
Enterprise Value | $31.97B | $167.31B |
Dividend Yield | 1.45% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Prologis (PLD) trades at $138.73, down 1.02% today, with a bearish technical signal from moving averages but strong fundamentals including a 45.79% net income margin and consistent earnings beats. Recent news highlights a major acquisition of SEGRO for $18.8 billion, expanding its European footprint, alongside a common stock offering to fund growth. Cash flow trends show volatility, with 2025 net cash flow negative at -$172.94 million but projected to rebound in 2026.
The outlook is positive due to robust earnings growth and strategic expansion, but risks include rising debt levels and integration challenges from the SEGRO deal. Analysts are bullish with a $159.22 consensus target, suggesting 15% upside, supported by institutional holdings and dividend payouts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
